These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

798 related articles for article (PubMed ID: 25413443)

  • 1. Predicting pathological outcomes in patients undergoing robot-assisted radical prostatectomy for high-risk prostate cancer: a preoperative nomogram.
    Abdollah F; Klett DE; Sood A; Sammon JD; Pucheril D; Dalela D; Diaz M; Peabody JO; Trinh QD; Menon M
    BJU Int; 2015 Nov; 116(5):703-12. PubMed ID: 25413443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer.
    Briganti A; Joniau S; Gontero P; Abdollah F; Passoni NM; Tombal B; Marchioro G; Kneitz B; Walz J; Frohneberg D; Bangma CH; Graefen M; Tizzani A; Frea B; Karnes RJ; Montorsi F; Van Poppel H; Spahn M
    Eur Urol; 2012 Mar; 61(3):584-92. PubMed ID: 22153925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer.
    Roumiguié M; Beauval JB; Filleron T; Benoit T; Rischmann P; de la Taille A; Salomon L; Soulié M; Malavaud B; Ploussard G
    BJU Int; 2014 Dec; 114(6b):E113-E119. PubMed ID: 24684584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the clinical benefit of a nomogram to predict specimen-confined disease at radical prostatectomy in patients with high-risk prostate cancer: An external validation.
    Hansen J; Becker A; Kluth LA; Rink M; Steuber T; Zacharias M; Briganti A; Fisch M; Graefen M; Chun FK
    Urol Oncol; 2015 Sep; 33(9):384.e1-8. PubMed ID: 26122714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy.
    Kumar A; Samavedi S; Mouraviev V; Bates AS; Coelho RF; Rocco B; Patel VR
    J Robot Surg; 2017 Mar; 11(1):37-45. PubMed ID: 27245233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgical and oncological outcomes in patients with a preoperative PSA value <4 ng/ml undergoing robot-assisted radical prostatectomy.
    Zugor V; Labanaris AP; Bauer RM; Witt JH
    Anticancer Res; 2012 May; 32(5):2079-83. PubMed ID: 22593492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgical and oncological outcomes in patients with preoperative PSA >20 ng/ml undergoing robot-assisted radical prostatectomy.
    Zugor V; Witt JH; Heidenreich A; Porres D; Labanaris AP
    Anticancer Res; 2012 May; 32(5):2091-5. PubMed ID: 22593494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncological outcomes after robot-assisted radical prostatectomy: long-term follow-up in 4803 patients.
    Sukumar S; Rogers CG; Trinh QD; Sammon J; Sood A; Stricker H; Peabody JO; Menon M; Diaz-Insua M
    BJU Int; 2014 Dec; 114(6):824-31. PubMed ID: 24053586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores.
    Briganti A; Larcher A; Abdollah F; Capitanio U; Gallina A; Suardi N; Bianchi M; Sun M; Freschi M; Salonia A; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2012 Mar; 61(3):480-7. PubMed ID: 22078338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting survival of patients with node-positive prostate cancer following multimodal treatment.
    Abdollah F; Karnes RJ; Suardi N; Cozzarini C; Gandaglia G; Fossati N; Bianchi M; Boorjian SA; Sun M; Karakiewicz PI; Montorsi F; Briganti A
    Eur Urol; 2014 Mar; 65(3):554-62. PubMed ID: 24094576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting survival of men with recurrent prostate cancer after radical prostatectomy.
    Dell'Oglio P; Suardi N; Boorjian SA; Fossati N; Gandaglia G; Tian Z; Moschini M; Capitanio U; Karakiewicz PI; Montorsi F; Karnes RJ; Briganti A
    Eur J Cancer; 2016 Feb; 54():27-34. PubMed ID: 26707594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. External validation of the updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection.
    Gacci M; Schiavina R; Lanciotti M; Masieri L; Serni S; Vagnoni V; Abdollah F; Carini M; Martorana G; Montorsi F
    Urol Int; 2013; 90(3):277-82. PubMed ID: 23296120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Yonsei nomogram to predict lymph node invasion in Asian men with prostate cancer during robotic era.
    Kim KH; Lim SK; Kim HY; Han WK; Choi YD; Chung BH; Hong SJ; Rha KH
    BJU Int; 2014 Apr; 113(4):598-604. PubMed ID: 24006951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncologic outcomes at 10 years following robotic radical prostatectomy.
    Diaz M; Peabody JO; Kapoor V; Sammon J; Rogers CG; Stricker H; Lane Z; Gupta N; Bhandari M; Menon M
    Eur Urol; 2015 Jun; 67(6):1168-1176. PubMed ID: 24996687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermediate-term cancer control outcomes in prostate cancer patients treated with robotic-assisted laparoscopic radical prostatectomy: a multi-institutional analysis.
    Abdollah F; Dalela D; Sood A; Sammon J; Jeong W; Beyer B; Fossati N; Rogers CG; Diaz-Insua M; Peabody J; Haese A; Montorsi F; Graefen M; Briganti A; Menon M
    World J Urol; 2016 Oct; 34(10):1357-66. PubMed ID: 26873596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
    Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
    Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extent of pelvic lymph node dissection and the impact of standard template dissection on nomogram prediction of lymph node involvement.
    Godoy G; Chong KT; Cronin A; Vickers A; Laudone V; Touijer K; Guillonneau B; Eastham JA; Scardino PT; Coleman JA
    Eur Urol; 2011 Aug; 60(2):195-201. PubMed ID: 21257258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.